Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era

Journal of Urology

Volumn 171, Issue 4, 2004, Pages 1525-1528

  Oefelein, Michael G ^a   Agarwal, Piyush K ^a   Resnick, Martin I ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen antagonists; Prostate; Prostatic neoplasms; Survival

Indexed keywords

ALKALINE PHOSPHATASE; ANDROGEN; ANTINEOPLASTIC AGENT; GLUCOCORTICOID; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGE DISTRIBUTION; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANAMNESIS; ARTICLE; BONE METASTASIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; SMOKING HABIT; TESTOSTERONE BLOOD LEVEL; URINARY TRACT DISEASE;

EID: 1642383644     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000118294.88852.cd     Document Type: Article

References (20)

1. Eisenberger, M. A.: Chemotherapy for hormone-resistant prostate cancer. In: Campbell's Urology, 7th ed. Edited by P. C. Walsh, A. B. Retik, E. D. Vaughan, Jr. and A. J. Wein. Philadelphia: W. B. Saunders Co., pp. 2648-2658, 1998
2. Halabi, S., Small, E. J., Kantoff, P. W., Kattan, M. W., Kaplan, E. B., Dawson, N. A. et al: Prognostic model predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol, 21: 1232, 2003
3. Berry, W. R., Laszlo, J., Cox, E., Walker, A. and Paulson, D.: Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer, 44: 763, 1979
4. Kelly, W. K., Scher, H. I., Mazumdar, M., Vlamis, V., Schwartz, M. and Fossa, S. D.: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol, 11: 607, 1993
5. Scher, H. I., Kelly, W., Zhang, Z. F., Ouyang, P., Sun, M., Schwartz, M. et al: Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst, 91: 244, 1999
6. Solaway, M. S., Ishikawa, S., van der Zwaag, R. and Todd, B.: Prognostic factors in patients with advanced prostate cancer. Urology, 33: 53, 1989
7. Smaletz, O., Scher, H. I., Small, E. J., Verbal, D. A., McMillan, A., Regan, K. et al: Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol, 20: 3972, 2002
8. Vogelzang, N. J., Crawford, E. D. and Zietman, A.: Current clinical trial design issues in hormone-refractory prostate carcinoma. Cancer, 82: 2093, 1998
9. Smith, D. C., Dunn, R. L., Strawderman, M. S. and Pienta, K. J.: Changes in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol, 16: 1835, 1998
10. Manni, A., Bartholomew, M., Caplan, R., Boucher, A., Santen, R., Lipton, A. et al: Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol, 6: 1456, 1988
11. Mulders, P. F., Dijkman, G. A., Fernandez del Moral, P., Theeuwes, A. G. and Debruyne, F. M.: Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group. Cancer, 65: 2758, 1990
12. Sylvester, R. J., Denis, L. and de Voogt, H.: The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC). Eur Urol, 33: 134, 1998
13. Ribeiro, M., Ruff, P. and Falkson, G.: Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol, 20: 605, 1997
14. Emrich, L. J., Piore, R. L., Murphy, G. P. and Brady, M. F.: Prognostic factors in patients with advanced stage prostate cancer. Cancer Res, 45: 5173, 1985
15. Kantoff, P. W., Halabi, S., Conaway, M. R., Picus, J., Kirshner, J., Hars, V. et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B9182 study. J Clin Oncol, 17: 2506, 1999
16. Oefelein, M. G., Feng, A., Scolieri, M. J., Ricchiutti, D. and Resnick, M. I.: Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology, 56: 1021, 2000
17. Albertsen, P. C., Hanley, J. A. and Murphy-Setzko, M.: Statistical considerations when assessing outcomes following treatment for prostate cancer. J Urol, 162: 439, 1999
18. Wiefurt, K. P., Yun, L., Castel, L. D., Timbie, J. W., Glendenning, A. and Schulman, K. A.: The impact of skeletal-related events on health-related quality of life in patients with metastatic prostate cancer. Ann Oncol, suppl., 13: 180, 2002
19. Vollmer, R. T., Kantoff, P. W., Dawson, N. A. and Vogelzang, N. J.: A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies. Clin Cancer Res, 5: 831, 1999
20. Matzkin, H., Eber, P., Todd, B., van der Zwaag, R. and Soloway, M. S.: Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer, 70: 2302, 1992